ANIX VS TRVI Stock Comparison

Performance

ANIX
10/100

ANIX returned -42.05% in the last 12 months. Based on SPY's performance of 13.09%, its performance is below average giving it a score of 10 of 100.

TRVI
10/100

TRVI returned -29.03% in the last 12 months. Based on SPY's performance of 9.73%, its performance is below average giving it a score of 10 of 100.

Analyst Price Targets

ANIX
75/100

1 analysts offer 12-month price targets for ANIX. Together, they have an average target of 8, the most optimistic target put ANIX at 8 within 12-months and the most pessimistic has ANIX at 8.

TRVI

"Analyst Price Targets" not found for TRVI

Sentiment

ANIX
67/100

ANIX had a bullish sentiment score of 66.58% across Twitter and StockTwits over the last 12 months. It had an average of 1.57 posts, 0.29 comments, and 1.43 likes per day.

TRVI
65/100

TRVI had a bullish sentiment score of 64.86% across Twitter and StockTwits over the last 12 months. It had an average of 1.75 posts, 0.12 comments, and 0.00 likes per day.

Technicals

ANIX
11/100

ANIX receives a 10 of 100 based on 14 indicators. 1 are bullish, 12 are bearish.

TRVI
21/100

TRVI receives a 21 of 100 based on 14 indicators. 2 are bullish, 10 are bearish.

Earnings

ANIX
61/100

ANIX has missed earnings 3 times in the last 20 quarters.

TRVI
40/100

TRVI has missed earnings 4 times in the last 20 quarters.

Profit

ANIX
10/100

Out of the last 20 quarters, ANIX has had 0 profitable quarters and has increased their profits year over year on 0 of them.

TRVI
10/100

Out of the last 20 quarters, TRVI has had 0 profitable quarters and has increased their profits year over year on 0 of them.

Volatility

ANIX
34/100

ANIX has had a lower than average amount of volatility over the last 12 months giving it a score of 34 of 100.

TRVI
44/100

TRVI has had a lower than average amount of volatility over the last 12 months giving it a score of 44 of 100.

All score calculations are broken down here to help you make more informed investing decisions

Anixa Biosciences, Inc. Summary

Nasdaq / ANIX

Healthcare

Biotechnology

Anixa Biosciences, Inc., a biotechnology company, develops therapies and vaccines focusing on critical unmet needs in oncology and infectious diseases. The company's therapeutics programs include the development of a chimeric endocrine receptor T-cell technology, a novel form of chimeric antigen receptor T-cell (CAR-T) technology focusing on the treatment of ovarian cancer; and the discovery and development of anti-viral drug candidates for the treatment of COVID-19 focused on inhibiting certain protein functions of the virus. Its vaccine programs comprise the development of a vaccine against triple negative breast cancer; and a preventative vaccine against ovarian cancer. The company is also developing immuno-therapy drugs against cancer. It has a collaboration agreement with MolGenie GmbH to discover and develop anti-viral drug candidates against COVID-19. The company was formerly known as ITUS Corporation and changed its name to Anixa Biosciences, Inc. in October 2018. Anixa Biosciences, Inc. was incorporated in 1982 and is based in San Jose, California.

Trevi Therapeutics, Inc. Common Stock Summary

Nasdaq / TRVI

Healthcare

Biotechnology

Trevi Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of Haduvio to treat serious neurologically mediated conditions. The company is developing Haduvio, an oral extended-release formulation of nalbuphine, which is in phase IIb/III clinical trial for the treatment of chronic pruritus, chronic cough in patients with idiopathic pulmonary fibrosis. It has a license agreement with Endo Pharmaceuticals Inc. to develop and commercialize products incorporating nalbuphine hydrochloride in any formulation. The company was incorporated in 2011 and is headquartered in New Haven, Connecticut.

Power up your portfolio